Hennion & Walsh Asset Management Inc. Has $2.26 Million Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT)

Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 34.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 265,372 shares of the company's stock after buying an additional 68,330 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.23% of Applied Therapeutics worth $2,256,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of APLT. Janus Henderson Group PLC raised its position in shares of Applied Therapeutics by 198.6% in the first quarter. Janus Henderson Group PLC now owns 6,414,642 shares of the company's stock valued at $43,555,000 after purchasing an additional 4,266,179 shares during the period. Propel Bio Management LLC increased its stake in shares of Applied Therapeutics by 13.7% in the first quarter. Propel Bio Management LLC now owns 6,111,906 shares of the company's stock worth $41,561,000 after purchasing an additional 736,924 shares during the period. Knoll Capital Management LLC increased its stake in shares of Applied Therapeutics by 1.8% in the first quarter. Knoll Capital Management LLC now owns 5,574,687 shares of the company's stock worth $37,908,000 after purchasing an additional 100,000 shares during the period. Frazier Life Sciences Management L.P. lifted its position in shares of Applied Therapeutics by 17.1% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company's stock worth $10,676,000 after purchasing an additional 333,278 shares during the last quarter. Finally, StemPoint Capital LP boosted its stake in Applied Therapeutics by 122.3% during the 1st quarter. StemPoint Capital LP now owns 2,017,016 shares of the company's stock valued at $13,716,000 after purchasing an additional 1,109,864 shares during the period. 98.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on APLT shares. Leerink Partners lifted their price target on Applied Therapeutics from $11.00 to $14.00 and gave the stock an "outperform" rating in a research report on Thursday, September 19th. William Blair raised shares of Applied Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Royal Bank of Canada reiterated an "outperform" rating and set a $12.00 target price on shares of Applied Therapeutics in a research note on Wednesday, July 17th. Finally, Citigroup raised their price target on shares of Applied Therapeutics from $8.00 to $11.00 and gave the stock a "buy" rating in a research report on Thursday, September 19th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Applied Therapeutics has an average rating of "Buy" and an average target price of $12.50.

Insider Activity at Applied Therapeutics

In other Applied Therapeutics news, CEO Shoshana Shendelman sold 119,591 shares of the firm's stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $5.93, for a total transaction of $709,174.63. Following the completion of the transaction, the chief executive officer now owns 4,690,839 shares in the company, valued at $27,816,675.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.60% of the stock is currently owned by insiders.

Applied Therapeutics Price Performance

Shares of NASDAQ APLT traded down $0.49 during trading hours on Friday, reaching $8.43. The stock had a trading volume of 1,692,765 shares, compared to its average volume of 1,834,721. The company has a market cap of $963.27 million, a price-to-earnings ratio of -4.58 and a beta of 2.04. Applied Therapeutics, Inc. has a twelve month low of $1.79 and a twelve month high of $9.39. The business's fifty day moving average is $7.19 and its two-hundred day moving average is $5.70.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The business had revenue of $0.14 million for the quarter, compared to analysts' expectations of $10.00 million. Sell-side analysts forecast that Applied Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.